Catalyst Pharmaceuticals Files 8-K
Ticker: CPRX · Form: 8-K · Filed: Jan 21, 2025 · CIK: 1369568
| Field | Detail |
|---|---|
| Company | Catalyst Pharmaceuticals, Inc. (CPRX) |
| Form Type | 8-K |
| Filed Date | Jan 21, 2025 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, financial-statements, exhibits
Related Tickers: CPRX
TL;DR
CPRX filed an 8-K, mostly standard financial docs. No major news.
AI Summary
On January 21, 2025, Catalyst Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, indicating routine corporate disclosures rather than a specific material event. No new financial figures or significant business developments were detailed in the provided excerpt.
Why It Matters
This filing indicates routine corporate disclosures and the submission of financial statements and exhibits, which is standard for publicly traded companies.
Risk Assessment
Risk Level: low — The filing appears to be a routine disclosure of financial statements and exhibits, with no indication of significant new risks or events.
Key Players & Entities
- CATALYST PHARMACEUTICALS, INC. (company) — Registrant
- January 21, 2025 (date) — Date of Report
- Delaware (jurisdiction) — State of Incorporation
- 355 Alhambra Circle Suite 801 Coral Gables , Florida 33134 (address) — Principal Executive Offices
FAQ
What is the primary purpose of this 8-K filing by Catalyst Pharmaceuticals, Inc.?
The primary purpose of this 8-K filing is to report 'Other Events' and to provide 'Financial Statements and Exhibits'.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on January 21, 2025.
In which state is Catalyst Pharmaceuticals, Inc. incorporated?
Catalyst Pharmaceuticals, Inc. is incorporated in Delaware.
What is the principal executive office address for Catalyst Pharmaceuticals, Inc.?
The principal executive office address is 355 Alhambra Circle Suite 801 Coral Gables, Florida 33134.
Does this filing indicate any specific new product launches or regulatory approvals?
The provided excerpt of the 8-K filing does not detail any specific new product launches or regulatory approvals; it focuses on 'Other Events' and 'Financial Statements and Exhibits'.
Filing Stats: 445 words · 2 min read · ~1 pages · Grade level 10.9 · Accepted 2025-01-21 16:30:15
Key Financial Figures
- $0.001 — Ticker Symbol Common Stock, par value $0.001 per share NASDAQ Capital Market CPR
Filing Documents
- d848918d8k.htm (8-K) — 24KB
- d848918dex991.htm (EX-99.1) — 9KB
- 0001193125-25-009573.txt ( ) — 160KB
- cprx-20250121.xsd (EX-101.SCH) — 3KB
- cprx-20250121_lab.xml (EX-101.LAB) — 18KB
- cprx-20250121_pre.xml (EX-101.PRE) — 11KB
- d848918d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits 99.1 Press release issued by the Company on January 21, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 2
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Catalyst Pharmaceuticals, Inc. By: /s/ Michael W. Kalb Michael W. Kalb Executive Vice President and Chief Financial Officer Dated: January 21, 2025 3